These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23596147)

  • 1. Incretin therapy and islet pathology: a time for caution.
    Kahn SE
    Diabetes; 2013 Jul; 62(7):2178-80. PubMed ID: 23596147
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
    Engel SS; Golm GT; Lauring B
    Diabetes; 2013 Oct; 62(10):e18. PubMed ID: 24065799
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
    Heine RJ; Fu H; Kendall DM; Moller DE
    Diabetes; 2013 Oct; 62(10):e16-7. PubMed ID: 24065798
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
    Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
    Diabetes; 2013 Oct; 62(10):e19-22. PubMed ID: 24065800
    [No Abstract]   [Full Text] [Related]  

  • 5. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
    Bonner-Weir S; In't Veld PA; Weir GC
    Diabetes Obes Metab; 2014 Jul; 16(7):661-6. PubMed ID: 24400596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
    Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
    Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
    Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
    Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novo Nordisk incretin leadership summit, Cape Town.
    Cardiovasc J Afr; 2012 Jun; 23(5):288-92. PubMed ID: 23077732
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
    Salehi M; Aulinger BA; D'Alessio DA
    Endocr Rev; 2008 May; 29(3):367-79. PubMed ID: 18292465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipotoxicity impairs incretin signalling.
    Poitout V
    Diabetologia; 2013 Feb; 56(2):231-3. PubMed ID: 23188391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 12. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
    Ueberberg S; Jütte H; Uhl W; Schmidt W; Nauck M; Montanya E; Tannapfel A; Meier J
    Diabetes Obes Metab; 2016 Dec; 18(12):1253-1262. PubMed ID: 27545110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
    Kang ZF; Deng Y; Zhou Y; Fan RR; Chan JC; Laybutt DR; Luzuriaga J; Xu G
    Diabetologia; 2013 Feb; 56(2):423-33. PubMed ID: 23188390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck M; Smith U
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of diabetic autonomic neuropathy on the incretin effect.
    Kazakos KA; Sarafidis PA; Yovos JG
    Med Sci Monit; 2008 Apr; 14(4):CR213-20. PubMed ID: 18376350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.